Covered recipient · General Payments record
TIMOTHY E BYUN
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$8,123.38
221 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $4,252.50 | 5 |
| Food and Beverage | $3,858.96 | 215 |
| Education | $11.92 | 1 |
By paying entity
PY2021 · entire year · sorted by reported total
Page 3 of 5; records 101–150 of 221 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
TIMOTHY E BYUN
NPI 1871545012 · CMS profile ID 356857
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
ORANGE, CA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 5; records 101–150 of 221 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1871545012?year=2021&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- TIMOTHY E BYUN, NPI 1871545012, CMS profile ID 356857. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 221 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1871545012?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). TIMOTHY E BYUN, NPI 1871545012, CMS profile ID 356857. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 221 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1871545012?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- TIMOTHY E BYUN, NPI 1871545012, CMS profile ID 356857, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 5; records 101–150 of 221 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1871545012?year=2021&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
221 matching records · $8,123.38 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–150 of 221.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Seagen Inc. | $16.72 | 06/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832142267 | CMS |
| Exelixis Inc. | $29.38 | 06/24/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 838869387 | CMS |
| GlaxoSmithKline, LLC. | $15.39 | 06/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 802506658 | CMS |
| E.R. Squibb & Sons, L.L.C. | $15.20 | 06/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783399933 | CMS |
| Seagen Inc. | $17.22 | 06/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832142261 | CMS |
| Myovant Sciences Inc. | $13.02 | 06/18/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834946651 | CMS |
| Coherus Biosciences Inc. | $18.00 | 06/17/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 855097491 | CMS |
| Janssen Biotech, Inc. | $15.31 | 06/16/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788770303 | CMS |
| AstraZeneca Pharmaceuticals LP | $1,387.50 | 06/14/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 830180003 | CMS |
| Pharmacyclics LLC, An AbbVie Company | $28.49 | 06/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 781008581 | CMS |
| E.R. Squibb & Sons, L.L.C. | $0.38 | 06/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783399943 | CMS |
| E.R. Squibb & Sons, L.L.C. | $14.58 | 06/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783399945 | CMS |
| AstraZeneca Pharmaceuticals LP | $15.97 | 06/10/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829865727 | CMS |
| GENZYME CORPORATION | $16.20 | 06/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843544089 | CMS |
| E.R. Squibb & Sons, L.L.C. | $12.53 | 06/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783399931 | CMS |
| Amgen Inc. | $18.48 | 06/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 826447179 | CMS |
| Pharmacyclics LLC, An AbbVie Company | $24.74 | 06/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 781008579 | CMS |
| AstraZeneca Pharmaceuticals LP | $19.02 | 06/04/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829864085 | CMS |
| Janssen Biotech, Inc. | $12.55 | 06/03/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788770297 | CMS |
| Karyopharm Therapeutics Inc. | $14.72 | 06/02/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845789289 | CMS |
| Amgen Inc. | $21.56 | 06/01/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 826447219 | CMS |
| Gilead Sciences, Inc. | $11.92 | 06/01/2021 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845871439 | CMS |
| AstraZeneca Pharmaceuticals LP | $15.47 | 05/28/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 830054161 | CMS |
| Seagen Inc. | $19.12 | 05/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832142259 | CMS |
| Exelixis Inc. | $22.24 | 05/20/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 838868687 | CMS |
| Celgene Corporation | $12.71 | 05/18/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783669033 | CMS |
| AstraZeneca Pharmaceuticals LP | $19.65 | 05/17/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 830200007 | CMS |
| AMAG Pharmaceuticals, Inc. | $29.80 | 05/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 847702219 | CMS |
| Rigel Pharmaceuticals, Inc. | $11.46 | 05/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 854324773 | CMS |
| AstraZeneca Pharmaceuticals LP | $20.46 | 05/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829724655 | CMS |
| Celgene Corporation | $14.54 | 05/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783669031 | CMS |
| Celgene Corporation | $15.41 | 05/10/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783669035 | CMS |
| Seagen Inc. | $21.51 | 05/10/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832142251 | CMS |
| E.R. Squibb & Sons, L.L.C. | $14.88 | 05/06/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783399923 | CMS |
| Amgen Inc. | $18.54 | 05/05/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 826447173 | CMS |
| AstraZeneca Pharmaceuticals LP | $8.83 | 05/05/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829747791 | CMS |
| Seagen Inc. | $16.03 | 05/05/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832142249 | CMS |
| Pharmacyclics LLC, An AbbVie Company | $22.73 | 04/29/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 781008577 | CMS |
| Amgen Inc. | $21.28 | 04/27/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 826447169 | CMS |
| AbbVie Inc. | $17.92 | 04/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794198851 | CMS |
| GlaxoSmithKline, LLC. | $16.20 | 04/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 802905333 | CMS |
| Seagen Inc. | $16.96 | 04/21/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832142237 | CMS |
| Seagen Inc. | $13.78 | 04/21/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832142241 | CMS |
| E.R. Squibb & Sons, L.L.C. | $5.42 | 04/20/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783399915 | CMS |
| Exelixis Inc. | $28.54 | 04/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 838868217 | CMS |
| Myovant Sciences Inc. | $7.48 | 04/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834946649 | CMS |
| Taiho Oncology, Inc. | $15.97 | 04/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843382063 | CMS |
| Karyopharm Therapeutics Inc. | $19.46 | 04/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845789287 | CMS |
| Amgen Inc. | $26.25 | 04/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 826541041 | CMS |
| AstraZeneca Pharmaceuticals LP | $1,665.00 | 04/11/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 830206057 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $236,520.43 | 59 |
| PY2024 | Principal investigator | $351,810.22 | 57 |
| PY2023 | Principal investigator | $441,384.47 | 42 |
| PY2022 | Principal investigator | $137,954.21 | 31 |
| PY2021 | Principal investigator | $167,046.51 | 28 |
| PY2020 | Principal investigator | $1,455,846.40 | 41 |
| PY2019 | Principal investigator | $110,652.36 | 37 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
59 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme LLC | $9,502.40 | 12/31/2025 | Non-covered Recipient Entity St. Joseph Hospital-The Center for Cancer Prevention and Treatment | An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib MK-7902 vs Cabozantinib for Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1,L1 Therapy | No dispute reported | 06/30/2026 | 1232931502 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $489.00 | 12/10/2025 | Non-covered Recipient Entity St. Joseph Hospital-The Center for Cancer Prevention and Treatment | An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib MK-7902 vs Cabozantinib for Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1,L1 Therapy | No dispute reported | 06/30/2026 | 1232931500 |
| Principal investigator 1 | Genentech, Inc. | $1,044.00 | 12/01/2025 | Non-covered Recipient Entity ST JOSEPH HOSPITAL OF ORANGE | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211659291 |
| Principal investigator 1 | PFIZER INC. | $1,400.00 | 11/26/2025 | Covered Recipient Teaching Hospital Providence Portland Medical Center | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228709212 |
| Principal investigator 1 | Genentech, Inc. | $478.13 | 11/25/2025 | Non-covered Recipient Entity ST JOSEPH HOSPITAL OF ORANGE | Neoadjuvant NSCLC | No dispute reported | 06/30/2026 | 1211659249 |
| Principal investigator 1 | Genentech, Inc. | $478.13 | 11/20/2025 | Non-covered Recipient Entity ST JOSEPH HOSPITAL OF ORANGE | Neoadjuvant NSCLC | No dispute reported | 06/30/2026 | 1211659254 |
| Principal investigator 1 | BioNTech SE | $1,200.00 | 10/29/2025 | Non-covered Recipient Entity ST JOSEPH HOSPITAL OF ORANGE | BNT122 | No dispute reported | 06/30/2026 | 1249017893 |
| Principal investigator 1 | BioNTech SE | $1,400.00 | 10/29/2025 | Non-covered Recipient Entity ST JOSEPH HOSPITAL OF ORANGE | BNT122 | No dispute reported | 06/30/2026 | 1249017895 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,800.00 | 10/29/2025 | Non-covered Recipient Entity PROVIDENCE MEDICAL FOUNDATION | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184253784 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,534.00 | 10/29/2025 | Non-covered Recipient Entity PROVIDENCE MEDICAL FOUNDATION | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184253786 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,550.00 | 10/29/2025 | Non-covered Recipient Entity PROVIDENCE MEDICAL FOUNDATION | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184253788 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $13,500.00 | 10/29/2025 | Non-covered Recipient Entity PROVIDENCE MEDICAL FOUNDATION | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184253791 |
| Principal investigator 1 | Genentech, Inc. | $128.00 | 10/23/2025 | Non-covered Recipient Entity ST JOSEPH HOSPITAL OF ORANGE | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211659295 |
| Principal investigator 1 | Genentech, Inc. | $1,078.00 | 10/22/2025 | Non-covered Recipient Entity ST JOSEPH HOSPITAL OF ORANGE | NAUTIKA1 previously LCMC4 | No dispute reported | 06/30/2026 | 1211659226 |
| Principal investigator 1 | Genentech, Inc. | $2,124.00 | 10/22/2025 | Non-covered Recipient Entity ST JOSEPH HOSPITAL OF ORANGE | NAUTIKA1 previously LCMC4 | No dispute reported | 06/30/2026 | 1211659229 |
| Principal investigator 1 | Genentech, Inc. | $2,500.00 | 10/10/2025 | Non-covered Recipient Entity ST JOSEPH HOSPITAL OF ORANGE | Neoadjuvant NSCLC | No dispute reported | 06/30/2026 | 1211659246 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,750.00 | 09/29/2025 | Non-covered Recipient Entity PROVIDENCE MEDICAL FOUNDATION | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175352100 |
| Principal investigator 1 | Genentech, Inc. | $1,552.00 | 09/25/2025 | Non-covered Recipient Entity ST JOSEPH HOSPITAL OF ORANGE | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211659287 |
| Principal investigator 1 | Genentech, Inc. | $478.13 | 09/17/2025 | Non-covered Recipient Entity ST JOSEPH HOSPITAL OF ORANGE | Neoadjuvant NSCLC | No dispute reported | 06/30/2026 | 1211659243 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $4,000.00 | 09/15/2025 | Non-covered Recipient Entity ST JOSEPH HOSPITAL | An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) | No dispute reported | 06/30/2026 | 1190313701 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $18,831.00 | 08/26/2025 | Non-covered Recipient Entity ST JOSEPH HOSPITAL | An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) | No dispute reported | 06/30/2026 | 1190313705 |
| Principal investigator 1 | BioNTech SE | $1,088.00 | 07/22/2025 | Non-covered Recipient Entity ST JOSEPH HOSPITAL OF ORANGE | BNT-122-01 | No dispute reported | 06/30/2026 | 1249017772 |
| Principal investigator 1 | Genentech, Inc. | $478.13 | 07/21/2025 | Non-covered Recipient Entity ST JOSEPH HOSPITAL OF ORANGE | Neoadjuvant NSCLC | No dispute reported | 06/30/2026 | 1211659239 |
| Principal investigator 1 | Janssen Research & Development, LLC | $31,333.00 | 07/21/2025 | Non-covered Recipient Entity PROVIDENCE MEDICAL FOUNDATION | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175352106 |
| Principal investigator 1 | Genentech, Inc. | $268.00 | 07/11/2025 | Non-covered Recipient Entity ST JOSEPH HOSPITAL OF ORANGE | NAUTIKA1 previously LCMC4 | No dispute reported | 06/30/2026 | 1211659176 |
| Principal investigator 1 | Genentech, Inc. | $130.00 | 07/11/2025 | Non-covered Recipient Entity ST JOSEPH HOSPITAL OF ORANGE | NAUTIKA1 previously LCMC4 | No dispute reported | 06/30/2026 | 1211659181 |
| Principal investigator 1 | Genentech, Inc. | $2,508.00 | 07/11/2025 | Non-covered Recipient Entity ST JOSEPH HOSPITAL OF ORANGE | NAUTIKA1 previously LCMC4 | No dispute reported | 06/30/2026 | 1211659185 |
| Principal investigator 1 | Genentech, Inc. | $2,508.00 | 07/11/2025 | Non-covered Recipient Entity ST JOSEPH HOSPITAL OF ORANGE | NAUTIKA1 previously LCMC4 | No dispute reported | 06/30/2026 | 1211659188 |
| Principal investigator 1 | Genentech, Inc. | $130.00 | 07/11/2025 | Non-covered Recipient Entity ST JOSEPH HOSPITAL OF ORANGE | NAUTIKA1 previously LCMC4 | No dispute reported | 06/30/2026 | 1211659194 |
| Principal investigator 1 | Genentech, Inc. | $217.47 | 07/11/2025 | Non-covered Recipient Entity ST JOSEPH HOSPITAL OF ORANGE | NAUTIKA1 previously LCMC4 | No dispute reported | 06/30/2026 | 1211659204 |
| Principal investigator 1 | Genentech, Inc. | $545.30 | 07/11/2025 | Non-covered Recipient Entity ST JOSEPH HOSPITAL OF ORANGE | NAUTIKA1 previously LCMC4 | No dispute reported | 06/30/2026 | 1211659207 |
| Principal investigator 1 | Genentech, Inc. | $268.00 | 07/11/2025 | Non-covered Recipient Entity ST JOSEPH HOSPITAL OF ORANGE | NAUTIKA1 previously LCMC4 | No dispute reported | 06/30/2026 | 1211659215 |
| Principal investigator 1 | Genentech, Inc. | $1,500.00 | 07/11/2025 | Non-covered Recipient Entity ST JOSEPH HOSPITAL OF ORANGE | NAUTIKA1 previously LCMC4 | No dispute reported | 06/30/2026 | 1211659218 |
| Principal investigator 1 | Genentech, Inc. | $2,500.00 | 07/11/2025 | Non-covered Recipient Entity ST JOSEPH HOSPITAL OF ORANGE | NAUTIKA1 previously LCMC4 | No dispute reported | 06/30/2026 | 1211659223 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,750.00 | 07/11/2025 | Non-covered Recipient Entity PROVIDENCE MEDICAL FOUNDATION | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175352132 |
| Principal investigator 1 | PFIZER INC. | $7,000.00 | 07/07/2025 | Covered Recipient Teaching Hospital Providence Portland Medical Center | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228709210 |
| Principal investigator 1 | BioNTech SE | $4,000.00 | 07/04/2025 | Non-covered Recipient Entity ST JOSEPH HOSPITAL OF ORANGE | BNT-122-01 | No dispute reported | 06/30/2026 | 1249017774 |
| Principal investigator 1 | Genentech, Inc. | $130.00 | 07/04/2025 | Non-covered Recipient Entity ST JOSEPH HOSPITAL OF ORANGE | NAUTIKA1 previously LCMC4 | No dispute reported | 06/30/2026 | 1211659196 |
| Principal investigator 1 | Genentech, Inc. | $2,508.00 | 07/04/2025 | Non-covered Recipient Entity ST JOSEPH HOSPITAL OF ORANGE | NAUTIKA1 previously LCMC4 | No dispute reported | 06/30/2026 | 1211659200 |
| Principal investigator 1 | Genentech, Inc. | $267.80 | 07/04/2025 | Non-covered Recipient Entity ST JOSEPH HOSPITAL OF ORANGE | NAUTIKA1 previously LCMC4 | No dispute reported | 06/30/2026 | 1211659212 |
| Principal investigator 1 | Genentech, Inc. | $956.26 | 06/17/2025 | Non-covered Recipient Entity ST JOSEPH HOSPITAL OF ORANGE | Neoadjuvant NSCLC | No dispute reported | 06/30/2026 | 1211659232 |
| Principal investigator 1 | ABBVIE INC. | $1,278.06 | 06/11/2025 | Non-covered Recipient Entity ST JOSEPH HOSPITAL THE CENTER FOR CANCER PREVENTION AND TREATMENT ORANGE CA | Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1202490851 |
| Principal investigator 1 | ABBVIE INC. | $750.00 | 06/11/2025 | Non-covered Recipient Entity ST JOSEPH HOSPITAL THE CENTER FOR CANCER PREVENTION AND TREATMENT ORANGE CA | Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1202490853 |
| Principal investigator 1 | BioNTech SE | $500.00 | 06/05/2025 | Non-covered Recipient Entity ST JOSEPH HOSPITAL OF ORANGE | BNT-122-01 | No dispute reported | 06/30/2026 | 1249017766 |
| Principal investigator 1 | Janssen Research & Development, LLC | $26,000.00 | 05/20/2025 | Non-covered Recipient Entity PROVIDENCE MEDICAL FOUNDATION | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175352066 |
| Principal investigator 1 | Janssen Research & Development, LLC | $22,471.00 | 05/20/2025 | Non-covered Recipient Entity PROVIDENCE MEDICAL FOUNDATION | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175352113 |
| Principal investigator 1 | BioNTech SE | $202.00 | 05/15/2025 | Non-covered Recipient Entity ST JOSEPH HOSPITAL OF ORANGE | BNT-122-01 | No dispute reported | 06/30/2026 | 1249017764 |
| Principal investigator 1 | Genentech, Inc. | $1,583.00 | 05/06/2025 | Non-covered Recipient Entity ST JOSEPH HOSPITAL OF ORANGE | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211659283 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,600.00 | 05/05/2025 | Non-covered Recipient Entity PROVIDENCE MEDICAL FOUNDATION | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175352058 |
| Principal investigator 1 | Genentech, Inc. | $478.13 | 04/25/2025 | Non-covered Recipient Entity ST JOSEPH HOSPITAL OF ORANGE | Neoadjuvant NSCLC | No dispute reported | 06/30/2026 | 1211659235 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,000.00 | 04/24/2025 | Non-covered Recipient Entity STJOSEPHHOSPITALOFORANGE | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS | No dispute reported | 06/30/2026 | 1184189341 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,500.00 | 04/24/2025 | Non-covered Recipient Entity STJOSEPHHOSPITALOFORANGE | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS | No dispute reported | 06/30/2026 | 1184189343 |
| Principal investigator 1 | BioNTech SE | $2,991.00 | 04/08/2025 | Non-covered Recipient Entity ST JOSEPH HOSPITAL OF ORANGE | BNT-122-01 | No dispute reported | 06/30/2026 | 1249017762 |
| Principal investigator 1 | Genentech, Inc. | $4,000.00 | 03/24/2025 | Non-covered Recipient Entity ST JOSEPH HOSPITAL OF ORANGE | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211659280 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $842.14 | 03/19/2025 | Non-covered Recipient Entity Saint Joseph Hospital | A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome in Erythropoiesis-Stimulating Agent naive Participants who are Non-Transfusion Dependent | No dispute reported | 06/30/2026 | 1235994105 |
| Principal investigator 1 | Genentech, Inc. | $128.00 | 03/03/2025 | Non-covered Recipient Entity ST JOSEPH HOSPITAL OF ORANGE | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211659277 |
| Principal investigator 1 | BioNTech SE | $120.00 | 01/23/2025 | Non-covered Recipient Entity ST JOSEPH HOSPITAL OF ORANGE | BNT-122-01 | No dispute reported | 06/30/2026 | 1249017738 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $36,739.00 | 01/16/2025 | Non-covered Recipient Entity SAINT JOSEPH HOSPITAL ORANGE | An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) | No dispute reported | 06/30/2026 | 1190312629 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $435.35 | 01/15/2025 | Non-covered Recipient Entity ST JOSEPH HOSPITAL | An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) | No dispute reported | 06/30/2026 | 1190313703 |